Skip to content
Japan
-
Kyowa Kirin invests US$118M in advanced biopharmaceutical manufacturing facility in Japan
This state-of-the-art facility is designed to support the early-phase development of biopharmaceuticals and is equipped with both good manufacturing practices (GMP)-compliant and pilot-scale manufacturing areas.
-
Marubeni invests US$300M for 60% stake in Sumitomo Pharma’s Asian business
Marubeni aims to leverage this opportunity by expanding its healthcare portfolio, which already includes pharmaceutical distribution businesses in China, the Middle East, and Africa.
-
US private equity firm KKR eyes acquisition of Topcon
This potential deal highlights the increasing activity of private equity firms in Japan, driven by favorable conditions such as corporate governance reforms, rising shareholder activism, and a weaker yen.
-
Ono Pharma secures global rights to Ionis’ Sapablursen for polycythemia vera
Polycythemia vera (PV) is a rare hematologic disease that affects the bone marrow, leading to an excessive production of red blood cells.
-
-
-
-
-
-
